Linear regression was performed on log-transformed IgG (anti-RBD/S) titers at the M3 and M4 to determine associations with sex, age groups or chronic disease for vaccinated individuals (Table 3)

Linear regression was performed on log-transformed IgG (anti-RBD/S) titers at the M3 and M4 to determine associations with sex, age groups or chronic disease for vaccinated individuals (Table 3). M2 (GM = 116.1 BAU/mL; CI: 92.3C146.1) were significantly higher than those found on PI HCW at Rabbit polyclonal to EIF4E FadD32 Inhibitor-1 recruitment (M1) (GM = 35.9 BAU/mL; CI:15.4C83.4), and the neutralizing antibodies (nAb) were similar between these groups, of 93.2 UI/mL (95% CI 73.2C118.5) vs. 84.1 UI/mL (95% CI 40.4C155.9), respectively. We detected around 10-fold higher IgG (anti-RBD/S) antibodies titers in M3 when compared with M2, with a slight but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers was correlated with IgG (anti-RBD/S) antibodies titers; however, in contrast to IgG (anti-RBD/S) antibodies titers, we did not detect a decrease in the nAb titer 36 days after a second vaccine dose uptake. At M4, a decrease of 8-fold in binding IgG (anti-RBD/S) and nAb was observed. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD/S) antibodies titers and nAb titers could be correlated, but an ongoing follow up of the cohort is required to better understand this correlation, and the duration of the immune response. 0.05. All statistical analyses were performed using Stata software, version 15.1 (StataCorp.2017. Stata Statistical Software, StataCorp, College Station, TX, USA). 2.9. Ethical Considerations The study complied with the relevant legal and ethical requirements. The study protocol was approved by the National Institute of Health Doctor Ricardo Jorge Health Ethics Committee. All participants provided their written informed consent for collection of data regarding demographic, social, and health information, blood samples and nasopharyngeal/oropharyngeal swabs. 3. Results Out of the 212 workers that were part of the INSA cohort on 15 June 2021, 132 were included FadD32 Inhibitor-1 in this FadD32 Inhibitor-1 study, and 114 were from the vaccinated and partially vaccinated group and 18 individuals were from the group with previous contamination, and had an RT-PCR positive test (= 14) FadD32 Inhibitor-1 or with a positive serological analysis with the detection of antibodies against SARS-CoV-2 in serum sample (= 4). These four individuals were therefore unaware of having been exposed to the SARS-CoV-2. From the vaccinated group, 84 were vaccinated against SARS-CoV-2, and 30 were partially vaccinated (Table 1). Vaccinated and partially vaccinated individuals had mostly taken the Comirnaty? vaccine (88.6%, = 101), followed by the Vaxzevria? (6.1%, = 7), the Spikevax (3.5%, = 4), and the others had COVID-19 Vaccine Janssen? (1.9%, = 2). In both groups, the majority were women (81% and 90%, respectively), and the mean age was lower for the vaccinated group (x? = 44 (23C67) versus x? = 57 (46C69)). Within the vaccinated group, over 68% reported working in the laboratory, whereas over 81% of the partially vaccinated group reported working in services that did not required conversation with the public. Regarding smoking habits, 11% of the fully vaccinated individuals and 23% of the partially vaccinated were reported to be smokers. Just under half of the vaccinated (48.7%) and 68.4% of the partially vaccinated participants reported at least one chronic disease. In both groups, over 70% of participants reported to have uptake the influenza vaccine in the previous season. Table 1 Vaccinated and partially vaccinated participants sociodemographic, work, and health characteristics. 0.001). Table 2 Geometric Mean (GM) of SARS-CoV-2 IgG (anti-RBD/S) concentration titers at four different moments for the full-vaccinated, partially.